Table 5.
Listed trials of investigational checkpoint inhibitors in lymphoma.
| Trial ID | Phase | Target(s) | Intervention(s) | Population(s) | Status |
|---|---|---|---|---|---|
| NCT03489343 | I | TIM-3 | Sym023 | Advanced malignancies, including lymphomas | Completed |
| NCT03311412 | I | TIM-3 LAG-3 |
Sym021 + Sym022 (LAG-3) Sym021 + Sym023 (TIM-3) Sym021 + Sym022 + Sym023 |
Advanced malignancies, including lymphomas | Recruiting |
| NCT02061761 | I | LAG-3 | BMS-986016 ± Nivolumab (PD-1) | Hematologic malignancies, including cHL, NHL, CLL, and MM | Active |
| NCT03538028 | I | LAG-3 | INCAGN02385 | Advanced malignancies, including DLBCL | Completed |
| NCT03365791 | II | LAG-3 | LAG525 + PDR001 (PD-1) | Advanced malignancies, including DLBCL | Completed |
| NCT03005782 | I | LAG-3 | REGN3767 ± Cemiplimab (PD-1) | Advanced solid malignancies or lymphomas | Recruiting |
| NCT03489369 | I | LAG-3 | Sym022 | Advanced malignancies, including lymphomas | Completed |
| NCT04254107 | I | TIGIT | SGN-TGT ± Pembrolizumab | Advanced malignancies, including cHL, DLBCL, and PTCL | Recruiting |
| NCT04353830 | I | TIGIT | IBI939 ± Sintilimab (PD-1) | Advanced malignancies (no further specification) | Recruiting |